Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Retained Earnings (2021 - 2026)

Atara Biotherapeutics filings provide 6 years of Retained Earnings readings, the most recent being -$2.0 billion for Q1 2026.

  • On a quarterly basis, Retained Earnings changed 0.47% to -$2.0 billion in Q1 2026 year-over-year; TTM through Mar 2026 was -$2.0 billion, a 0.47% change, with the full-year FY2025 number at -$2.0 billion, down 25273412.5% from a year prior.
  • Retained Earnings hit -$2.0 billion in Q1 2026 for Atara Biotherapeutics, roughly flat from -$2.0 billion in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $8000.0 in Q4 2024 to a low of -$2.0 billion in Q3 2024.
  • Median Retained Earnings over the past 5 years was -$1.9 billion (2023), compared with a mean of -$1.4 billion.
  • Biggest five-year swings in Retained Earnings: soared 100.0% in 2024 and later plummeted 25273412.5% in 2025.
  • Atara Biotherapeutics' Retained Earnings stood at -$1.7 billion in 2022, then dropped by 16.31% to -$2.0 billion in 2023, then soared by 100.0% to $8000.0 in 2024, then plummeted by 25273412.5% to -$2.0 billion in 2025, then decreased by 0.21% to -$2.0 billion in 2026.
  • The last three reported values for Retained Earnings were -$2.0 billion (Q1 2026), -$2.0 billion (Q4 2025), and -$2.0 billion (Q3 2025) per Business Quant data.